UCB (Union Chimique Belge) is a global biopharmaceutical company headquartered in Brussels, Belgium. Founded in 1928, the company transitioned from industrial chemicals to pharmaceuticals, developing key drugs such as Zyrtec, Keppra, and Cimzia. Specializing in treatments for central nervous system disorders, inflammatory conditions, and oncology, UCB is committed to advancing medical research and improving patient outcomes.